Next-Gen Solutions through Innovation & Collaboration
The 4th Edition of the India Biopharma Leaders Conclave (IBLC), held on June 13-14 at Le Meridien, Hyderabad, showcased pioneering solutions in the biopharmaceutical sector. Featuring key industry players and innovators, the event delved into critical discussions on advancing biopharma technologies, enhancing quality standards, and optimizing supply chain strategies in line with current global demands. Powered by Rockwell Automation and organized by BlueTech Media, with JNC as the presenting partner, the conclave drew over 200 attendees, including stakeholders from various sectors of the biopharmaceutical industry.
“Smart Labtech’s role as associate partner elevated the 4th India Biopharma Leaders Conclave, aligning innovation and quality with the event’s groundbreaking biopharmaceutical discussions.“
Smart Labtech, the progenitor of Neo Science Hub (NSH), proudly served as an associate partner for the event. Smart Labtech’s association with the conclave not only underlines its dedication to fostering industry growth and collaboration but also highlights its role in setting new benchmarks within the sector. This partnership marks a significant stride towards advancing the industry’s standards and driving transformative changes across the biopharmaceutical ecosystem.
The sessions of IBLC 2024, enriched by contributions from leading experts, focused on addressing the pressing challenges and seizing opportunities within the rapidly evolving biopharma landscape, offering extensive networking and collaboration opportunities.
“As an associate partner, Smart Labtech was instrumental in the success of the 4th Edition of the India Biopharma Leaders Conclave at Le Meridien, Hyderabad. Its commitment to innovation and quality echoed throughout the event, enhancing discussions on biopharmaceutical advances and industry challenges.“
Inauguration
The 4th Edition of IBLC was inaugurated with insightful opening remarks by Assistant Drugs Controller (India), Vinay Kumar Gupta, who represented the Chief Guest, Dr. A. Ram Kishan, Deputy Drugs Controller, CDSCO, Hyderabad. Gupta emphasized the significant impact of biosimilars and biologics on the Indian pharmaceutical landscape, reflecting on his role in the formulation of CDSCO’s biosimilar guidelines while posted in Delhi. His speech underscored the conclave’s pivotal role in promoting essential discussions around these key areas, setting a collaborative tone for the event that would focus on innovation and regulatory advancements in the biopharmaceutical sector.
Challenges & Seizing Opportunities
The 4th Edition of the India Biopharma Leaders Conclave (IBLC) hosted an engaging panel discussion on “Biosimilars: Current Status, Future Challenges & Opportunities,” moderated by Dr. Shubhadeep Sinha of the Hetero Group. Esteemed panelists, including Mannan Khambati from Bharat Serum & Vaccines Ltd, Dr. Anurag Tiwari of Zumutor Biologics Pvt. Ltd, Dr. Y Sridhar Reddy from Hetero Group, Jagdish Bennale of OmniBRX Biotechnologies Pvt Ltd, and Dr. Uday Harle from Kashiv Biosciences NJ, USA, delved into the complexities and prospects of the biosimilars industry.
The discussion illuminated the intricate landscape of biosimilars, addressing both current advancements and the hurdles that lay ahead. The experts explored the evolving regulatory frameworks, market penetration strategies, and the critical role of innovation in propelling biosimilars towards a promising future. This panel not only highlighted the significant progress within the sector but also shed light on strategic measures necessary to overcome impending challenges, setting a forward-thinking agenda for stakeholders across the globe.
Future of Biosimilars
The panel discussion titled “Need for R&D in Biosimilars – Entering the Next Phase,” moderated by Dr. Ramesh Matur, Senior Vice President of R&D at Biological E Limited, highlighted the evolving landscape of biosimilar research and development. Panelists including Mr. Mannan Khambati, Associate Vice President at Bharat Serum & Vaccines Ltd; Dr. Anurag Tiwari, Assistant Vice President at Zumutor Biologics Pvt. Ltd; Dr. Y Sridhar Reddy, Vice President CDMA at Hetero Group; Jagdish Bennale, GSO at OmniBRX Biotechnologies Pvt Ltd; and Dr. Uday Harle, Assistant Vice President and Global Head of Clinical Development at Kashiv Biosciences NJ, USA, contributed their insights. They discussed the shift from generic production to innovative biosimilar solutions, emphasizing the need for significant R&D investment.
The conversation covered overcoming regulatory challenges, enhancing manufacturing efficiency through new technologies, and the critical role of collaboration among industry stakeholders to foster innovation and ensure the safety and efficacy of biosimilars. The panel underscored that the future of biosimilars hinges on robust R&D strategies that not only replicate but innovate, meeting global standards and patient needs.
CAR T-Cell Therapy
Moderated by Dr. Amit Awasthi, Senior Professor at the Translational Health Science & Technology Institute, this panel discussion delved into the cutting-edge realm of CART T cell therapy. Esteemed panelists including Dr. Kishore J.R. Kunapuli, Chief Scientific Officer- Cell Therapy Division at Pulse Pharmaceuticals Pvt. Ltd.; Dr. Akhil Kumar, Chief Medical Officer at Aurigene Oncology; and Dr. Bajarang Kumbhar, Assistant Professor at the Department of Biological Sciences, NMIMS, explored the latest advancements and the future outlook in CART T cell therapy.
They discussed innovative therapeutic strategies and the integration of new technologies that are set to revolutionize cancer treatment. Emphasizing the importance of research collaborations between academia and industry, the panel highlighted key challenges such as scalability, cost, and regulatory hurdles. The conversation also underscored the transformative potential of CART T cell therapy in offering targeted and effective treatment options for patients, pushing the boundaries of personalized medicine.
Cell & Gene Therapy
Moderated by Dr. Akhilesh Sharma, President & Chief Medical Officer of Alkem Laboratories, this engaging panel discussion tackled the dynamic and rapidly evolving landscape of cell and gene therapy. The discussion featured insights from prominent industry experts including Dr. Murali K Addepalli, CSO of Lextro Bio; Dr. Ananda Gopu Perumal, Managing Director & R&D Head of Lysine Biotech Pvt Ltd; Dr. Renjitha Gopurappilly, CSO of NK Therapeutics; and Dr. Arun Anand, Board Director & COO of Immuneel Therapeutics.
The panelists explored the current state and the exciting future of cell and gene therapy development and manufacturing. They addressed the scientific breakthroughs driving the field, the challenges of scaling production, and the regulatory landscape shaping the industry. Discussions also focused on the potential of these therapies to offer transformative treatments for previously incurable diseases, emphasizing the critical need for innovation in therapeutic development and delivery systems.
Regulatory Guidelines
The panel, expertly moderated by Ms. Rajni Jha, a Biopharma & Pharmaceutical Regulatory Consultant, provided a comprehensive overview of the regulatory frameworks governing biosimilars. The discussion featured esteemed panelists such as Dr. Anup Choudhury, MD, Medical Director of Global Clinical Development at Novartis; Dr. Prasun Guha, Head of Regulatory Affairs at Dr. Reddy’s Laboratories; and Dr. Akshaya S. Odak, Head of Regulatory (Biotech) at Lupin Ltd. Together, they delved into the intricate regulatory challenges and strategies associated with biosimilar development.
The panelists discussed key aspects such as the evolving regulatory guidelines in major markets, the importance of maintaining compliance with these standards, and the impact of regulatory pathways on the speed to market. They also explored strategies for navigating complex regulatory environments, ensuring product quality and efficacy, and aligning global operations to meet diverse international standards. This session was invaluable for professionals seeking deeper insights into the regulatory landscape of biosimilars.
Way for Future Therapies
In the spirited panel discussion titled “Future Direction for Product Development in Biosimilars” at the 4th Edition of the India Biopharma Leaders Conclave, experts delved into the evolving biosimilars landscape. Moderated by Mr. Sanjay B. Shah, Founder & Principal Consultant at XenPharm Services, the session featured insights from Dr. Khokan Debnath, Senior General Manager of Regulatory Affairs, Pharmacovigilance & Quality at Wockhardt Ltd, Mr. Satish Makkina, General Manager – Biologics at Procell Biologics Pvt Ltd, and Mr. Siva Sankar Mahamkali, Director at Aragen Life Sciences Pvt Ltd.
These panelists discussed the integration of innovative technologies, the importance of robust regulatory strategies, and comprehensive market analysis in shaping the future of biosimilars development. They highlighted the need for dynamic adaptability in research and development strategies to keep pace with international standards and market demands, ensuring the successful rollout of biosimilar products globally.
Biopharma – Digital Innovation
During the “Transformative Digitalization in Biopharma” panel at the 4th Edition of the India Biopharma Leaders Conclave, moderated by Dr. Subhash Thuluva, Sr. Vice President & Head – Clinical Development at Biological E Limited, key industry leaders discussed the crucial role of digital technologies in advancing biopharmaceutical processes. The panel included Mr. Madan Kumar Y, Regional Sales Manager at Rockwell Automation, Mr. Pavan Badale, Head of Process Excellence SCM at Novartis, Mr. Anil Roy, Vendor Alliance Lead Associate Director at Novartis Healthcare, and Dr. Kunal Joshi, Head of Marketing Cell & Gene Therapy – CAR T at Dr. Reddy’s Laboratories.
They explored how digital tools and automation are revolutionizing biopharma from research and development to supply chain management and manufacturing. Emphasizing the importance of digital maturity, the panelists discussed strategies for integrating cutting-edge technologies such as AI, machine learning, and IoT to enhance efficiency, improve product quality, and accelerate time to market in the competitive biopharma landscape.
Quality Assurance Challenges
In the “Developing Quality Assurance Standards for Biologics & Biosimilars” panel discussion, moderated by Dr. Ranjan Chakrabarti, a noted Consultant in R&D Strategy for Biologics, the focus was sharply on the evolving quality assurance landscape in biologics and biosimilars. Panelists included Mr. Arvind Kushwaha, Head of QA for Biologics at Dr. Reddy’s Laboratories, Dr. Annu Uppal, Director of Scientific Affairs at USP, Mr. M. Gopi Reddy, Vice President and Head of Corporate Compliance and CQA at Sun Pharma, and Dr. Mukesh Kumar, M.D & Senior Vice President & Head of Clinical R&D at Cipla.
The discussion highlighted the critical need for robust quality standards to ensure the efficacy and safety of biologics and biosimilars. The panelists shared insights on current challenges and advancements in quality assurance practices, emphasizing the importance of stringent regulatory frameworks to align with international standards. They explored strategies for overcoming complexities in the development and manufacturing processes of biologics, stressing the need for continuous innovation and adaptation in quality control methodologies to meet global regulatory demands and ensure patient safety.
Biopharma Supply Chains
In the panel discussion titled “Shaping the Future with our Supply Chain to Patent Strategic Framework,” moderated by Mr. Prasad Satam, Vice President of Packaging Research Development, the focus was squarely on enhancing the biopharmaceutical supply chain for better strategic outcomes. The panel included Ms. Indira Singampalli, Biologics Procurement Lead for Supply Chain Management at Dr. Reddy’s Laboratories, and Mr. Lakshmi Narayana Dommarajula, Associate Director of SCM at Aragen Life Sciences.
The conversation centered on the crucial role of supply chain management in the biopharmaceutical sector, particularly in relation to the patenting process and ensuring efficient, compliant operations. The panelists discussed strategies for optimizing supply chain frameworks to support rapid and innovative product development while maintaining compliance with global regulatory standards. They emphasized the importance of integrating advanced technologies and predictive analytics to improve supply chain resilience and responsiveness. This strategic approach aims to not only streamline operations but also secure patents effectively, ensuring a competitive edge in the fast-evolving biopharma landscape.
IBLC 2024: Industry Synergy
Overall, the IBLC 2024, powered by Rockwell Automation with JNC as the presenting partner and organized by BlueTech Media, was a comprehensive and well-coordinated event. Supported by exhibit partner MP Biomedicals and associate partners including Smart Labtech, PharmaNXT, and Ami Polymers, the conclave attracted over 200 participants. It offered a platform for insightful discussions on a wide range of pertinent topics such as quality standards, digitized supply chains, and emerging trends in the biopharma industry, providing valuable networking and collaboration opportunities to industry leaders and professionals. Thanks to partnerships like that of Smart Labtech, participants gained invaluable insights into the future of biosimilars and biologics, setting a new benchmark for innovation and collaborative success in the industry.
– Kinnera M
